RemedEase Inc. – Amy Rix

Download Report

Transcript RemedEase Inc. – Amy Rix

Inc.
Amy D. Rix, Interim CEO, Founder
Stop the Bleed with… NOseBLEED
…
Social/Public Issues…
Problems that can be associated with frequent
nosebleeds:
o Embarrassing especially when out in public
o Loss of dignity
o Loss of clothes
o Having to stop what you are doing
o Loss of time in a game (sports)
2
Solution: Stop the bleed with…
Benefits of NOseBLEED
•
•
•
•
Is non-invasive to the nose
Does not restrict normal breathing
Stops nosebleeds in ~1-2 minutes
Product is digestible
Technology
Technology
Technology
Technology
Technology
Sizable Need
• 2003 Study – 440 million total US nosebleeds per year
o Benninger and Marple - medical study (published/peer reviewed)
• 2008 Market Research Study- 700 million recurrent
nosebleeds per year
o Leading online survey company
Market
Market
(more than 1 per month)
Business Model/Exit
• Contract Manufacturing
• Joint-venture distributors
―Cardinal Health
―McKesson
• Direct sales model
― Breathe Right Strips (CNS Inc.)
― DURABOND (Closure Medical Corp.)
Partner and Exit Options
• CPC Licensing/Acquisition Options
―Johnson & Johnson (Closure Medical Corp., DURABOND)
―GSK
• Medical Supply Licensing/Acquisition Options
―McKesson
―Cardinal Health
Business
Business
Financial Return
Year
1
2
3
4
5
($ Millions)
$648.0
$673.9
$700.9
$1,403.8
$1,460.0
3%
6%
9%
12%
15%
$19.4
$40.4
$63.1
$168.4
$219.0
Gross Margin
% of Revenue
$6.6
$13.7
$21.4
$57.3
$74.5
34%
34%
34%
34%
34%
EBITDA
% of Revenue
$3.7
$8.8
$14.4
$44.8
$61.3
18.9%
21.8%
22.8%
26.6%
28.0%
Market Size*
Market Penetration**
Revenue
* Total Addressable Market (top 2 market segments yr 1-3, all segments yr 4-5)
** Source 2008 Market Study, Propensity to Buy Results = 18%
Financials
Value Creation
Seed Round Milestones:
Series A Milestones:
•
•
•
•
•
•
•
•
• $100 million revenue
Regulatory opinions Prototypes –
Material selection –
• Cash flow positive
Market research –
•
Segment strategy FDA approval – Ongoing
Manufacturing partner(s) – Ongoing
Partner agreement and
exit
• IP Continuation
Sterilization process – Ongoing
~$350K
Financials
$2.5 Million
Milestones